1 / 10

Microprosthetic Implant Implant for the Treatment of Erectile Dysfunction

Microprosthetic Implant Implant for the Treatment of Erectile Dysfunction. Matt Schwartz and Robert Douglas Advisor – Dr. Franz Baudenbacher. Thesis. A microprosthetic drug delivery implant has the potential to provide a biomimetic treatment option for erectile dysfunction.

coral
Télécharger la présentation

Microprosthetic Implant Implant for the Treatment of Erectile Dysfunction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Microprosthetic Implant Implant for the Treatment of Erectile Dysfunction Matt Schwartz and Robert Douglas Advisor – Dr. Franz Baudenbacher

  2. Thesis • Amicroprosthetic drug delivery implant has the potential to provide a biomimetic treatment option for erectile dysfunction. • Minimally invasive • Patient compliance • Targeted drug release and control

  3. Erectile Dysfunction Background • Erectile Dysfunction (ED) • Prevalence in men 40-70 = 52%1 • Current treatment options • Prescription oral pills • Injection therapy • Penile prosthetics • Drug therapy market size • $3.1 billion in 2005 • Estimated growth of 6.5% annually through 20102

  4. Pathophysiology • Physiology of erection • Erectile tissue – cavernous smooth muscles • Low blood flow in flaccid state • Stimulation causes arterioles to dilate3 • Neurophysiologoy • Cavernous nerves – neurovascular control of erection/detumescence • Dorsal nerve – sensory function • Pathology of ED • Psychogenic • Neurogenic • Estimated at 10-19% • Iatrogenic • Arteriogenic • Combination

  5. Problem and Solution • Diagnostics are expensive and inefficient • “There is a pressing need for new technologies for diagnosing and treating communicable and non-communicable diseases”1 • Benefits of syringe design • Parallel testing based on symptom and/or circumstance • Easy to administer • Disposable • Low power consumption (plunger driven flow) • Rapid and reliable results (MEMS) • Low cost

  6. Completed Work • Researched diseases and diagnostic assays • Investigated current technologies for blood filtration

  7. Ongoing Work • Design for proof of concept experiment • Filtration mechanism • Membrane • Nanofibers • Design specific mechanism • Single disease and assay selection • HIV – Immunoassay • Malaria – Immunochromatography • Cancer – Immunoassay (i.e. prostate specific antigen) • Compare efficiency of syringe to standard assay processes • Specificity • Sensitivity • Timing

  8. Future Work • Extend proof of concept results to further design • Calculate maximum possibilities for parallel testing • Explore avenues for prototype manufacturing

  9. Conclusions • Primary focus – Determining the most suitable test for proof of concept • Secondary focus – Designing filter for syringe implementation • Tertiary focus – Symptomatic, geographical, and situational based diagnostic groupings • d

  10. References • Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Urology 1994; 151: 54-61. • Elder, Melissa. Men’s Health: The Worldwide Market for Current and Emerging Drug Therapies, 2nd ed. Kalorma Information. May 2006. • Robert C. Dean, MD and Tom F. Lue, MD. Physiology of penile erection and pathophysiology of erectile dysfunction. UrolClin North Am. 2005 November; 32(4): 379-v.

More Related